Daniel Meressa

A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

Andrew Nunn, Patrick Phillips, Sarah Meredith et al. · New England Journal of Medicine · 2019 · 402 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

Ruth Goodall, Sarah Meredith, Andrew Nunn et al. · The Lancet · 2022 · 145 citations · Full text

Public Health, Infectious Diseases, Pharmacotherapy +11

Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia—an observational cohort study

Daniel Meressa, Rocio Hurtado, Jason R. Andrews et al. · Thorax · 2015 · 105 citations · Full text

Public Health, Health Sciences, Infectious Disease Control +17

Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment

D. Abate, Yared Tedla, Daniel Meressa et al. · The International Journal of Tuberculosis and Lung Disease · 2014 · 37 citations

Life Sciences, Genetics, Infectious Diseases +17

Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial

Laura Roșu, Jason Madan, Ewan Tomeny et al. · The Lancet Global Health · 2022 · 19 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +15